Tahoe Forest hires new physician at Incline Village hospital tahoedailytribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tahoedailytribune.com Daily Mail and Mail on Sunday newspapers.
uniQure Inc.: uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients
~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~
LEXINGTON, Mass. and AMSTERDAM, May 13, 2021showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to AAV5, and no relationship between AAV5 NAbs and the tolerability of the therapy.
The data were featured on Wednesday, May 12, 2021 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in an oral presentation by Michael Recht, M.D., Ph.D., M.B.A., professor of pediatrics, division of hematology and oncology at the Oregon Health & Science University School of Medicine. These data were previously presented at a medical meeting late last year.
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
~ Further Supports Potential for AAV5 Gene Therapies to be Viable Treatments in Nearly All Patients
~ Data Presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting ~
LEXINGTON, Mass. and AMSTERDAM, May 13, 2021 (GLOBE NEWSWIRE) uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, yesterday presented 26-week clinical data from the pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec showing clinical benefit in hemophilia B patients with pre-existing neutralizing antibodies (NAbs) to AAV5, and no relationship between AAV5 NAbs and the tolerability of the therapy.
The data were featured on Wednesday, May 12, 2021 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in an oral presentation by Michael Recht, M.D., Ph.D., M.B.A., professor of pediatrics, division of hematology and oncology at the Oregon Health & Science University School
ABIM Foundation Recognizes Best Medical Professionalism Articles prleap.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prleap.com Daily Mail and Mail on Sunday newspapers.